Abstract: Protein kinase C (PKC) signalling is critically involved in the control of blood pressure. Angiotensin-converting enzyme inhibitors (ACEi) affect PKC expression and activity, which are partially associated with the responses to ACEi. We examined whether PRKCA (protein kinase C, alpha) polymorphisms (rs887797 C>T, rs1010544 T>C and rs16960228 G>A), or haplotypes, and gene-gene interactions within the ACEi pathway affect the antihypertensive responses in 104 hypertensive patients treated with enalapril as monotherapy. Patients were classified as poor responders (PR) or good responders (GR) to enalapril if their changes in mean arterial pressure were lower or higher than the median value, respectively. Multi-factor dimensionality reduction was used to characterize interactions among PRKCA, NOS3 (nitric oxide synthase 3) and BDKRB2 (bradykinin receptor B2) polymorphisms. The TC+CC genotypes for the rs1010544 polymorphism were more frequent in GR than in PR (p = 0.037). Conversely, the GA+AA genotypes for the rs16960228 polymorphism, and the CTA haplotype, were more frequent in PR than in GR (p = 0.040 and p = 0.008, respectively). Moreover, the GG genotype for the PRKCA rs16960228 polymorphism was associated with PR or GR depending on the genotypes for the rs2070744 (NOS3) and rs1799722 (BDKRB2) polymorphisms (p = 0.012). Our results suggest that PRKCA polymorphisms and gene-gene interactions within the ACEi pathway affect the antihypertensive responses to enalapril.
Hypertension is a complex disease that affects approximately one billion individuals and is the most prevalent modifiable risk factor for cardiovascular events, including stroke and coronary heart disease [1, 2] . Angiotensin-converting enzyme inhibitors (ACEi) are widely used to treat hypertension because they significantly reduce disability and mortality [3] . While the main mechanism of action for ACEi involves the reduction of angiotensin II formation [3] , a secondary mechanism is related to vasodilation produced by nitric oxide (NO) as a result of endothelial nitric oxide synthase (NOS3) activation [4, 5] . Importantly, both mechanisms seem to be affected by protein kinase C (PKC) signalling [6] [7] [8] [9] [10] [11] [12] .
PKC is a ubiquitous enzyme that comprises 12 different isoforms, which play several physiological roles and mediate both positive and negative effects on cellular events [13] . PKC functions include modulation of ions channel, secretion and exocytosis, gene expression, cell growth and proliferation [14, 15] . Furthermore, PKC signalling is critically involved in the vascular control mechanisms of blood pressure [13, [16] [17] [18] . In line with these roles, experimental studies have shown that ACEi affect PKC expression and activity, thereby influencing the responses to these drugs [6] [7] [8] [9] 11, 12] . Therefore, it is possible that variations in genes encoding PKC isoforms may affect the antihypertensive responses to ACEi.
Notably, the rs16960228 polymorphism of the gene encoding PKCa (PRKCA, protein kinase C, alpha), one of the major PKC isoforms expressed in endothelial cells [19] , has recently been associated with responses to antihypertensive drugs in a genomewide association study (GWAS) of hypertensive patients [20, 21] . However, no previous study has examined whether PRKCA polymorphisms and haplotypes affect the antihypertensive responses to ACEi. Therefore, we focused here on the rs16960228 polymorphism and further examined the rs887797 and rs1010544 polymorphisms, which have been shown to affect PRKCA expression [20, 22] .
In addition, it is possible that interactions among PRKCA polymorphisms and other genes within the ACEi pathway may influence the responses to these drugs. Interestingly, PKCa increases NOS3 transcription and up-regulates NOS3 activity by phosphorylating Ser1179, leading to enhanced NO production and vasodilation [10, 19, 23] . Accordingly, ACEi treatment increases tissue bradykinin levels [4] , thus stimulating bradykinin receptors on endothelial cells [24] , which may result in NOS3 up-regulation mediated by PKCa [10] . Interestingly, we have found that polymorphisms of the genes encoding bradykinin receptor B2 (BDKRB2) and NOS3 are associated with the antihypertensive responses to ACEi enalapril [25, 26] . However, it has not been previously examined whether polymorphisms in PRKCA gene interact with BDKRB2 and NOS3 genes to modify the responses to enalapril. This is relevant as gene-gene interactions must be taken into account in pharmacogenomics [25, [27] [28] [29] .
In the present study, we examined whether PRKCA polymorphisms (rs887797, rs1010544 and rs16960228), or the haplotypes formed by them, affect the response to antihypertensive therapy in 104 patients classified as poor and good responders to enalapril. In addition, we examined whether interactions among the PRKCA polymorphisms and the previously studied NOS3 (rs2070744, rs3918226, 4b/4a VNTR and rs1799983) and BDKRB2 (rs1799722 and BE1 + 9/-9) polymorphisms [25, 26] are associated with the responses to enalapril.
Materials and Methods
Patients. This study was approved by the Institutional Review Board at Ribeirao Preto Medical School of University of Sao Paulo. All patients were recruited from the Cardiology Division of the Arac ßatuba Health Center (Arac ßatuba, SP, Brazil) and each patient signed an informed consent form. We studied 104 hypertensive patients with systolic blood pressure (SBP) ≥140 and ≤179 mmHg and diastolic blood pressure (DBP) ≥90 and ≤109 mmHg. Office blood pressure measurement was obtained from the average of three blood pressure readings on at least two office visits with individuals in the seated position, according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure [1] . We excluded patients with evidence of severe or secondary hypertension, diabetes and hepatic or renal dysfunction.
Antihypertensive responses to enalapril. Office SBP and DBP were recorded with a semi-automatic blood pressure monitor (OMRON â -HEM-433 INT, Bannockburn, Illinois, USA) before and after enalapril treatment [30] . Mean blood pressure (MBP) was calculated using the average of three different systolic and diastolic blood pressure measurements, with intervals of 1 min. between each other, according to the formula MBP=(SBP+2*DBP)/3. While most patients were never treated (n = 78), a group of patients underwent a washout period for at least 2 weeks (n = 26), which has been described to be enough to abolish the effects of previous antihypertensive treatments on physiological parameters [31] . Patients underwent physical examination, laboratorial analysis and evaluation of medical history. After initial examination, patients were treated for 60 days with enalapril as monotherapy, at the doses of 10 mg/day (n = 48) or 20 mg/ day (n = 56), according to judgement by the physician and taking into consideration the number of risk factors and the previous history of treatment of patients that underwent washout. The response to enalapril was calculated as the change in MBP (DMBP) obtained from the difference between the MAP before and after enalapril treatment, as previously established [25] . Patients were classified as poor responders (PR) or good responders (GR) when their DMBP were below or above the median value of the DMBP distribution, respectively. After blood pressure measurements, venous blood samples were collected and genomic DNA was extracted by a salting-out method and stored at -20°C until analysed.
Genotyping. Genotypes for the PRKCA rs887797, rs1010544 and rs16960228 polymorphisms were determined by TaqMan Allele Discrimination Assays (assay IDs: C_7475926_10, C_27229274_10 and C_34546218_10, respectively; Applied Biosystems, Foster City, CA, USA). TaqMan PCR was carried out in a total volume of 10 ll (5 ng of template DNA, 19 Taqman Genotyping Master Mix and 19 Taqman Allele Discrimination Assay) placed in 96-well PCR plates. Thermal cycling was performed in standard conditions and fluorescence was recorded by StepOnePlus Real-Time PCR equipment (Applied Biosystems). Genotyping quality was monitored using previously determined both positive and negative controls. In addition, we have randomly repeated 10% of the whole sample and obtained 100% of consistency. The results were analysed with manufacturer's software.
Genotypes for the NOS3 rs2070744, rs3918226 and rs1799983 polymorphisms were determined by Taqman Allele Discrimination Assays (Applied Biosystems) as described elsewhere [25] . Moreover, genotypes for the NOS3 4b/4a VNTR polymorphism were determined by PCR, and genotypes for the BDKRB2 rs1799722 and BE1 + 9/-9 polymorphisms were determined by PCR amplification followed by DNA sequencing as described elsewhere [25] .
Haplotype inference. Haplotypes frequencies were inferred using the Bayesian statistical-based program PHASE (version 2.1; http:// www.stat.washington.edu/stephens/software.html) [32] . The possible haplotypes including the three PRKCA polymorphisms (rs887797, rs1010544 and rs16960228) were as follows: CTG, CTA, CCG, CCA, TTG, TTA, TCA and TCG. The haplotypes with observed frequencies equal to 0% in at least one group or <5% in all groups were excluded from subsequent analysis. A value of p < 0.0125 was considered significant after Bonferroni's correction: 0.05/number of observed haplotypes. LD plots were characterized by calculating D' and LOD (log of the likelihood odds ratio, a measure of confidence in the value of D') among the PRKCA polymorphisms for the PR and GR groups of hypertensive patients using the Haploview software (version 4.2; http://www.broad.mit.edu/mpg/haploview/). LD plots were also evaluated for Europeans and Africans using genotype data from HapMap.
Statistical analysis. The clinical and laboratorial characteristics of patients classified as PR and GR to enalapril were compared by unpaired t-test (parametric data), Mann-Whitney test (nonparametric data), chi-square test or Fisher's tests (categorical variables) as appropriate. Deviation from the Hardy-Weinberg equilibrium was evaluated by chi-square test.
Genotype, allele and haplotype distributions were compared between PR and GR by multi-variate logistic regressions. Linear regression analysis and nonlinear fitting routines were performed using JMP â software (SAS Institute, Cary, NC, USA) to assess univariate relations between variables. In addition, a bivariate analysis was also performed to assess the potential confounding influence of each covariate on the relation between PRKCA genotypes, alleles and haplotypes and the response to enalapril. Responses to enalapril were considered as dependent variables, while PRKCA genotypes, alleles and haplotypes, as well as age, gender and ethnicity were considered as independent variables. Additionally, we evaluated the effects of PRKCA genetic markers on changes in SBP, MBP and DBP in response to enalapril using one-way ANOVA or unpaired t-test, as appropriate. To confirm these findings, we performed multiple linear regression analysis (JMP â software) adjusting for age, gender and ethnicity. A value of p < 0.05 was considered significant for clinical and laboratorial characteristics, and for PRKCA genotype and allele analysis.
Given the sample size of this study, we obtained a statistical power of 80% with an a value of 0.05, estimated using the PGA Matlab software [33] to detect an odds ratio of 2.5. In addition, we used G*Power 3.1.9.2 [34, 35] to calculate the statistical power taking into account four independent variables (age, gender, ethnicity and PRKCA genotypes/haplotypes), with an a value of 0.05. Power analysis of the effects of genotypes (f 2 =0.23) and haplotypes (f 2 =0.18) on changes in MBP in response to enalapril revealed a statistical power of 98% and 94%, respectively.
Multi-factor dimensionality reduction (MDR) identifies interactions of genotypes for their ability to classify them into poor and good responder groups through cross-validation (CV) steps and permutation testing [29, 36] . The best interaction model was the one that had the maximum testing score and CV consistency (CVC). Permutation testing was carried out to determine the statistical significance of the best model [27, 36] .
Results
The characteristics of the 104 hypertensive patients enrolled in this study are shown in table 1. Significant reduction in office SBP and DBP was observed after treatment with enalapril (p < 0.001). To assess whether PRKCA polymorphisms and haplotypes could affect the antihypertensive responses to enalapril, the patients were classified as poor responders (PR) or good responders (GR) (see Materials and Methods). We found no differences in gender, ethnicity, age, body mass index or in any laboratorial parameters between PR and GR groups (table 1; p > 0.05). In addition, while blood pressure was lower after treatment with enalapril in both groups (p < 0.001), baseline SBP and DBP was higher in GR (p < 0.05).
The distribution of genotypes for the PRKCA polymorphisms showed no deviation from Hardy-Weinberg equilibrium (all p > 0.05). table 2 shows the comparison of PRKCA genotype and allele distributions between PR and GR by multi-variate logistic regression analysis. Interestingly, GR showed higher frequencies of the TC+CC genotypes for the rs1010544 polymorphism than PR (table 2; p < 0.05). Conversely, PR showed higher frequencies of the GA+AA genotypes and the A allele for the rs16960228 polymorphism than GR (table 2; both p < 0.05). No significant differences in genotype and allele frequencies for the rs887797 polymorphism were observed between groups (table 2; p > 0.05). In addition, we compared PRKCA genotype and allele frequencies between PR and GR according to dosage of enalapril (Table S1 ). While we observed similar results in patients taking 20 mg/day, we found no effects on the responses to enalapril 10 mg/day (Table S1) .
The results for NOS3 and BDKRB2 single-locus analyses in the PR and GR are shown in Table S2 , which are in line with our previous findings [25] . The TC genotype and the C allele for the NOS3 rs2070744 polymorphism were more frequent in the GR group [25] . The TT genotype for the BDKRB2 rs1799722 polymorphism was more frequent in the PR group (although not significant), and this may be due to differences in sample size. Importantly, patients with any missing genotype data for these polymorphisms were not considered in the interaction analyses. table 3 shows the comparison of PRKCA haplotype distributions between PR and GR by multi-variate logistic regression analysis. We observed higher frequencies of the CTA haplotype in PR than in GR (table 3; p < 0.05), but this finding did not resist to correction for multiple comparisons. However, when PR and GR were stratified according to dosage of enalapril (Table S1 ), we found that the CTA haplotype is more frequent in PR than in GR taking enalapril 20 mg/day (Table S1 ; p = 0.008).
We also evaluated the effects of PRKCA genotypes and haplotypes on changes in SBP, MBP and DBP ( fig. 1 ), which are in line with comparisons between PR and GR (tables 2 and 3). Although the rs1010544 polymorphism has marginally affected the changes in MBP after treatment with enalapril in the unadjusted analyses ( fig. 1B ; p = 0.08), we observed that the TC+CC genotypes were associated with more intense decreases in MBP in response to enalapril after adjusting for covariates (p < 0.05; data not shown). Moreover, the GA or AA genotypes for the rs16960228 polymorphism were associated with lower decreases in MBP and DBP after treatment with enalapril compared with the GG genotype ( fig. 1C ; p < 0.05). The rs887797 polymorphism and haplotypes showed no effects on blood pressure in response to enalapril ( fig. 1A,D ; p < 0.05). Adjustment for covariates in multiple linear regression analysis did not change these effects (data not shown).
In order to assess the LD pattern among the PRKCA polymorphisms, we compared the D' and LOD values for the PR and GR groups with the Europeans and Africans from HapMap ( Figure S1 ). Notably, the highest LD values were observed between the rs1010544 and rs16960228 polymorphisms for the Europeans from HapMap (D'=1, LOD=0.49) and for the GR group (D'=0.690, LOD=0.06).
Finally, we examined whether interactions among the PRKCA, NOS3 and BDKRB2 polymorphisms were associated with the PR or GR group. We found a significant interaction fig. 2 . The combinations of the GG genotype for the PRKCA rs16960228 polymorphism with the TC or TT genotypes for the NOS3 rs2070744 polymorphism were more frequent in the GR or PR groups, respectively. These combinations are significant when combined with the CC genotype for the BDKRB2 rs1799722 polymorphism ( fig. 2 ; p < 0.05). We also examined whether interactions among PRKCA, NOS3 and BDKRB2 polymorphisms were associated with PR and GR groups according to the dosage of enalapril. Interestingly, we found the same combinations of genotypes for the PRKCA rs16960228 and NOS3 rs2070744 polymorphisms with PR and GR in response to enalapril 20 mg/day (Table S3 and Figure S2 ). However, we found no significant interactions of genotypes with PR and GR in response to enalapril 10 mg/day (data not shown).
Discussion
This study is the first to evaluate whether PRKCA polymorphisms and haplotypes, and gene-gene interactions with NOS3 and BDKRB2 polymorphisms, affect the antihypertensive responses to ACEi. In the present study, we focused on the widely prescribed ACEi enalapril, taking into account its effectiveness and prolonged action compared with other classical ACEi, like captopril, allowing a convenient single-daily administration [37, 38] . Our main findings are as follows: (i) PRKCA genotypes affect the responses to enalapril; (ii) the CTA haplotype is associated with worse responses to enalapril; and (ii) significant interactions among PRKCA, NOS3 and BDKRB2 genotypes modify the responses to enalapril. It is widely acknowledged that PKC plays important roles in the vascular mechanisms that control blood pressure [13] . In vascular smooth cells, PKC contributes to the contraction induced by angiotensin II [39] . Indeed, PKC phosphorylates C-kinase-activated protein phosphatase-1 inhibitor 17 kDa, which in turn inhibits myosin light chain (MLC) phosphatase, enhances MLC phosphorylation and increases vascular smooth cells contraction [40] . In addition, PKC mediates angiotensin II-induced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation, leading to oxidative stress and vasoconstriction [41] . On the other hand, in endothelial cells, PKC up-regulates NO signalling and contributes to vasodilation [10, 19, 23] . Although PKC exists in at least 12 isoforms [13] , these endothelial effects are mainly attributed to PKCa, one of the major isoforms expressed in vascular endothelium [19] . Interestingly, PKCa phosphorylates NOS3 at Ser1179, promoting enzyme activation [19] . Moreover, PKCa may induce NOS3 up-regulation in response to bradykinin, resulting in increased NO production [10] . Given that ACEi enhances bradykinin levels [4] , which activate bradykinin receptors on endothelial cells [24] , it is possible that these drugs may up-regulate PKCa signalling, as suggested by experimental studies [7, 8, 11] . Consistent with these ideas, we examined here whether polymorphisms of the gene encoding PKCa (PRKCA) affect the antihypertensive responses to the ACEi enalapril. Notably, the GA+AA genotypes for the rs16960228 PRKCA polymorphism were associated with better responses to hydrochlorothiazide and worse responses to atenolol in a GWAS [20, 21] . These contrasting findings may be explained by the different pharmacological mechanisms activated by thiazide diuretics and b-blockers [42] . To obtain further information about the effects of the rs16960228 polymorphism on the pharmacogenetics of antihypertensive drug responses, we tested whether it would affect the responses to enalapril. We found that the GA+AA genotypes (and the A allele) are associated with worse responses to enalapril. Interestingly, hypertensive patients carrying the GG genotype showed reduced PRKCA expression compared with GA+AA carriers [20] . Accordingly, ACEi may lead to up-regulation in PKCa signalling [7, 8, 11] , contributing to vasodilation and blood pressure responses due to NOS3 activation. Therefore, it is possible that the GG genotype for the rs16960228 polymorphism, which reduces PRKCA expression [20] , can also enhance the responses to drugs that increase PKCa, such as ACEi. Conversely, it seems reasonable to suggest that PKCa signalling could be less affected by ACEi in patients carrying the GA+AA genotypes, resulting in worse responses to these drugs. However, the molecular mechanisms supporting these suggestions remain to be proved. Moreover, the associations reported here must be replicated and the results confirmed across different populations [43] .
We next further examined the PRKCA rs887797 and rs1010544 polymorphisms which were shown to affect PRKCA expression in peripheral blood mononuclear cells [22] . While we found no effect of the rs887797 polymorphism, the TC+CC genotypes for the rs1010544 polymorphism were associated with better responses to enalapril. We Table 4 . MDR interaction models among the PRKCA, NOS3 and BDKRB2 polymorphisms in hypertensive patients classified as poor responders (PR, n = 52) and good responders (GR, n = 52) to enalapril. then performed LD analysis to correlate it with the reported functional rs16960228 polymorphism [20] . Interestingly, we found the highest LD values between rs1010544 and rs16960228 polymorphisms for the Europeans and the GR group ( Figure S1 ), which could explain the associations. However, the LD patterns may reflect the population history, and distinct haplotype blocks within the PRKCA gene were previously reported [22] . Therefore, LD among PRKCA polymorphisms should be explored in other populations to interpret the associations including the rs1010544 polymorphism, and further studies are needed to show how this polymorphism may affect PRKCA expression. We also analysed PRKCA haplotypes, which may provide improved genetic information than the analysis of single genetic markers [44, 45] . Although PRKCA haplotypes did not significantly affect the responses to enalapril in the analysis including the total number of patients, we found that CTA haplotype is associated with worse responses to enalapril 20 mg/day. This finding is in line with previous studies showing that the effects of polymorphisms or haplotypes on the responses to antihypertensive drugs are more evident at higher doses [26, 46, 47] . Interestingly, the CTA haplotype includes the T and A alleles for the rs1010544 and rs16960228 polymorphisms, respectively, which are involved with worse responses to enalapril. Therefore, we suggest that the CTA haplotype may increase PKCa expression, and consequently lead to worse responses to enalapril. However, further studies are required to address the functionality of this haplotype.
We then further examined whether other polymorphisms in the ACEi pathway may modify the responses to enalapril. Indeed, we found that GG genotype for the PRKCA rs16960228 polymorphism is associated with better responses to enalapril (table 2 and fig. 1 ). However, we found that the GG genotype for this polymorphism is associated with GR or PR depending on the rs2070744 (NOS3) and rs1799722 (BDKRB2) genotypes ( fig. 2) . These findings further highlight the relevance of gene-gene interactions in pharmacogenomics [25, [27] [28] [29] . However, the present study has not been designed to address the underlying molecular mechanisms explaining the interactions among PRKCA, NOS3 and BDKRB2 genes associated with enalapril response. Indeed, given that these gene-gene interactions could affect NOS3 activity and NO bioavailability, evaluating circulating nitrite levels and plasma NOS3 activity may be a possible approach to clarify this issue. In this regard, we have shown that NOS3 polymorphisms modify plasma and blood nitrite concentrations [48, 49] . Therefore, further studies are required to investigate the effects of interactions among PRKCA, NOS3 and BDKRB2 genes on circulating nitrite levels and NOS3 activity in patients treated with ACEi.
As a limitation of our study, we should mention the relatively low number of patients included. However, the present study was not underpowered (see Materials and Methods). Importantly, it should be noted that we included in our study only hypertensive patients in monotherapy with enalapril, never treated or those who underwent a washout period for at least 2 weeks before receiving enalapril-only treatment. Although this strategy has enabled us to prevent the interference of other antihypertensive drugs that are usually necessary in hypertension therapy, it has limited the number of patients that could be included in our study. In fact, more than two-thirds of hypertensive patients require two or more drugs to control blood pressure effectively [1] . Nevertheless, our sample size was enough to achieve an adequate statistical power. Another issue that has not been addressed in this study includes the evaluation of the effects of PRKCA polymorphisms on parameters of oxidative stress, such as thiobarbituric acid-reactive species (TBARS) and 8-isoprostane. Indeed, given that PKC may induce oxidative stress via NADPH oxidase activation, it is possible that PRKCA polymorphisms may affect levels of oxidative stress markers in patients taking ACEi, and therefore, further studies should address this possibility.
In conclusion, our findings suggest that PRKCA polymorphisms affect the antihypertensive responses to enalapril. While the TC+CC genotypes for the rs1010544 polymorphism are associated with better responses to enalapril, the GA+AA genotypes for the rs16960228 polymorphism and the CTA haplotype are associated with worse responses to this ACEi. Moreover, we found significant interactions among PRKCA, NOS3 and BDKRB2 genotypes associated with enalapril responses. Our findings may help understand the gene-gene Fig. 2 . The best MDR model of interaction among PRKCA rs16960228, NOS3 rs2070744 and BDKRB2 rs1799722 polymorphisms in hypertensive patients classified as poor responders (PR, n = 52) and good responders (GR, n = 52) to enalapril. The distributions of PR (left bars) and GR (right bars) are illustrated for each combination of genotypes. The light grey cells are labelled as GR to enalapril, dark grey cells are labelled as PR to enalapril, and white cells are labelled as unknown. The best interaction model was the one that had the maximum testing score and CV consistency (table 4). Permutation testing was carried out to determine the statistical significance of the best model. interactions within the ACEi pathway, and provide novel information to pharmacogenetics of antihypertensive drug responses.
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